Full metadata record

DC Field Value Language
dc.contributor.authorChu, Yeonjeong-
dc.contributor.authorReddy, B. Raja Sekhara-
dc.contributor.authorGajulapalli, V. Pratap Reddy-
dc.contributor.authorBabu, K. Sudhakar-
dc.contributor.authorKim, Eunha-
dc.contributor.authorLee, Sanghee-
dc.date.accessioned2024-01-19T16:00:59Z-
dc.date.available2024-01-19T16:00:59Z-
dc.date.created2021-09-02-
dc.date.issued2020-12-15-
dc.identifier.issn0960-894X-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/117682-
dc.description.abstractType I Interferon (IFN) signaling plays an important role in the immune defense system against virus infection and in the innate immune response, thus IFNs are widely used as anti-viral agents and treatment for immune disorder or cancer. However, there is a growing demand for novel small-molecule IFN inducer due to tolerance, toxicity, or short duration of action following direct administration of IFNs. In this study, we assessed arylpiperazine (ARP) as a new core skeleton of IFN inducer. To investigate structure-activity relationship, we designed and synthesized a series of ARP analogues and evaluated the ability to stimulate IFN response in THP-1 human monocyte cells. Compound 5i was identified as a potent type I IFN inducer as it significantly increased cytokine secretion and increased expression of various IFN-stimulating genes which are representative biomarkers of type I IFN pathway. Our results suggested a beneficial therapeutic potential of 5i as an anti-viral agent.-
dc.languageEnglish-
dc.publisherPergamon Press Ltd.-
dc.subjectMULTIPLE-SCLEROSIS-
dc.subjectHEPATITIS-
dc.subjectDISEASES-
dc.subjectGAMMA-
dc.subjectBETA-
dc.titleDesign, synthesis, and biological evaluation of N-arylpiperazine derivatives as interferon inducers-
dc.typeArticle-
dc.identifier.doi10.1016/j.bmcl.2020.127613-
dc.description.journalClass1-
dc.identifier.bibliographicCitationBioorganic & Medicinal Chemistry Letters, v.30, no.24-
dc.citation.titleBioorganic & Medicinal Chemistry Letters-
dc.citation.volume30-
dc.citation.number24-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000595378800018-
dc.identifier.scopusid2-s2.0-85094216931-
dc.relation.journalWebOfScienceCategoryChemistry, Medicinal-
dc.relation.journalWebOfScienceCategoryChemistry, Organic-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.relation.journalResearchAreaChemistry-
dc.type.docTypeArticle-
dc.subject.keywordPlusMULTIPLE-SCLEROSIS-
dc.subject.keywordPlusHEPATITIS-
dc.subject.keywordPlusDISEASES-
dc.subject.keywordPlusGAMMA-
dc.subject.keywordPlusBETA-
dc.subject.keywordAuthorInterferon inducer-
dc.subject.keywordAuthortype I Interferon-
dc.subject.keywordAuthorArylpiperazine-
dc.subject.keywordAuthorAnti-viral agent-
dc.subject.keywordAuthorInnate immunity-
Appears in Collections:
KIST Article > 2020
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE